controlled trial adjuvant immunotherapy murine monoclonal antibody resectable pancreatic cancer prospective multicentric trial patients hospitals resectable pancreatic cancer patients Whipple resection weeks surgery patients intravenous IV treatment mg mg dose mg days monoclonal antibody MoAb Behringwerke AG Marsburg Germany additional anti-cancer treatment murine immunoglobulin Ig antibody human pancreatic cancer cells antibody-dependent cellular cytotoxicity ADCC study groups respect age sex tumor staging patients minor toxicity abdominal pain immunotherapy months end recruitment period patients treatment control groups living patients alive recurrent progressive cancer disease Median survival time days range days days range days treatment control groups authors IV treatment antibody helpful resectable pancreatic cancer study first data passive immunotherapy solid cancer 